Portrai Inc.

👀 Four Must-see Visualization Tools in Spatial Biology 👀 Exciting advancements in spatial biology are the field with groundbreaking visualization tools. Portrai has recently written an in-depth review of four must-see visualization tools in spatial biology: Neuroglancer, MERSCOPE VIZUALIZER, Xenium Explorer, and CELLxGENE. These tools are revolutionizing how we interpret and interact with complex datasets. Curious to know which tool is best suited for your research needs? Dive into our brief review to explore their unique features and potential applications: Weekly Data Spotlight (Jul 31. 2024) https://lnkd.in/g54GHB7C Join the conversation and stay ahead in the race for superior visualization in spatial biology! 😄

Understanding the Termination of the AMG 794 Clinical Trial: Insights from Spatial Transcriptomics Data 🔬 Amgen recently exited the competitive development of Claudin 6 (CLDN6) therapies, halting the Phase 1 clinical trial of AMG 794, a CLDN6xCD3 bispecific T-cell engager (BiTE) targeting high-grade non-small cell lung cancer (NSCLC) and epithelial ovarian cancer (EOC). This decision, made on July 5th, 2024, has left many in the biotech community seeking answers, especially since there were no changes in the drug’s safety profile. At Portrai, we conducted a postmortem analysis to uncover the potential reasons behind this decision. Our findings shed light on the complexities of intratumoral heterogeneity and the role of CLDN6-based T cell engagers in lung adenocarcinoma (LUAD). Key Insights from Our Analysis: 🔍 Intratumoral Heterogeneity: The efficacy of T cell engagers relies heavily on the colocalization of target expression and T cell distribution within tumors. Our data indicated that regions with high CLDN6 expression but low T cell infiltration may be resistant to CLDN6-based therapies. This is supported by negative correlations between CLDN6 and immune enrichment scores in LUAD and OV from TCGA data. 📊Comparative Analysis: Compared to TROP2, CLDN6 demonstrates a highly discordant intratumoral distribution of targets and T cells. This discordance may contribute to the ineffectiveness of CLDN6-based therapies, necessitating further investigation. 🧬Therapeutic Efficacy and Toxicity: Our PortraiTARGET pipeline evaluates the therapeutic effects and potential toxicity of T cell engager targets through various checkpoints, assessing intratumoral T cell-target colocalization, target expression, and target specificity at both microenvironmental and organ levels. Our comprehensive analysis suggests that CLDN6’s low colocalization with T cells and low intratumoral expression likely played a significant role in the trial’s termination. This highlights the importance of selecting targets that maximize therapeutic effects while minimizing toxicity. By leveraging large-scale data-driven target discovery, we aim to improve the selection of T cell engagers, ultimately leading to more effective cancer treatments. #Biotech #CancerResearch #ClinicalTrials #SpatialTranscriptomics #TCellEngagers #PortraiTARGET #LungCancer

🌟 New Publication Alert! 🌟 We are excited to share our latest research publication: "Spatial transcriptomics unveils landscape of resistance to concurrent chemo-radiotherapy in hypopharyngeal squamous cell carcinoma: the role of SPP1+ macrophages" Key findings include: Identification of SPP1 as a crucial gene with significantly higher expression in CCRT-resistant samples, specifically within macrophages. Discovery of SPP1+ macrophages interacting with malignant epithelial cells through SPP1-CD44 and SPP1-ITGB1 ligand-receptor pairs, primarily localized in peri-tumoral and intra-tumoral regions. These insights suggest that SPP1+ macrophages contribute to the resistant phenotype in hypopharyngeal SCC by modulating the TME and interacting with cancer cells. Understanding these interactions offers valuable insights into CCRT resistance mechanisms and may guide the development of targeted therapies to improve patient outcomes. 🔍 Read the full preprint here: https://lnkd.in/gQGZjtWp #CancerResearch #SpatialTranscriptomics #CCRTResistance #HypopharyngealSCC #Macrophages #Oncology #Biomarkers #TargetedTherapies #Research #Portrai

🚀 Connectomics Data: What’s Different from Spatial transcriptomics? 🚀 Hey everyone! On May 10th, Harvard’s Lichtman Lab and Google Research Connectomics dropped a massive connectomics dataset. We’re talking about 1.4 petabytes of electron microscope (EM) data from a tiny part of the human brain. This incredible feat shows off the power of cutting-edge algorithms and open data. In our latest blog post, we dive into how this new H01 dataset stacks up against the 3D MERFISH dataset. Spoiler alert: both have unique strengths that could change the game for drug discovery and understanding neuropathological mechanisms. Curious to learn more about how spatial biology is revolutionizing science? Check out our blog! Link: https://lnkd.in/guaBKjzE

🚀Two Spatial Transcriptomics Technologies Meet: Visium and Xenium"🚀 In this edition of our “Weekly Data Spotlight,” we explore the paper "High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis." 🌟 This fascinating study, featuring the Visium-Xenium paired dataset from 10x Genomics, offers groundbreaking insights into breast cancer tissue, showcasing the transformative potential of spatial genomics. Discover how advanced techniques like Visium and Xenium reveal intricate details of the tumor microenvironment, and learn about Portrai’s innovative SuperST algorithm designed to enhance spatial data resolution. Stay tuned for more cutting-edge research and join us on our mission to revolutionize precision medicine! Read the full article here: [https://lnkd.in/gxn2WREa] #TechBlog #Biotech #SpatialTranscriptomics #PrecisionMedicine #Portrai #WeeklyDataSpotlight

🚀 Exciting News! Introducing Portrai’s Tech Blog 🚀 We are thrilled to announce the launch of our new tech blog at Portrai! 🎉 Our blog will be your go-to source for the latest insights and developments in #SpatialTranscriptomics and AI-driven biotechnology. We are kicking off with our “Weekly Data Spotlight,” where we explore fascinating data and highlight the latest research trends. Our first feature dives into a groundbreaking study, “Molecularly Defined and Spatially Resolved Cell Atlas of the Whole Mouse Brain,” led by Professor Xiaowei Zhuang from Harvard University. This research expands spatial transcriptomics from 2D to 3D, providing incredible insights into the neural cell types of the mouse brain. 🧠✨ Join us on this journey as we bring cutting-edge science to your fingertips. Stay tuned for more weekly updates and in-depth analyses. Let’s push the boundaries of precision medicine together! 🌟🔬 Check out the first article here: [https://bit.ly/45ru91t] #TechBlog #Biotech #SpatialTranscriptomics #PrecisionMedicine #Portrai #WeeklyDataSpotlight

🚀 Decipher Cancer Microbiome with #SpatialTranscriptomics! 🚀 #Cancer #Microbiome #SpatialTranscriptomics #Bioinformatics #Portrai We are thrilled to announce the publication of our latest research article, "Analysis of Unmapped RNA-seq Data from Cancer Spatial Transcriptome to Decipher Cancer Microbiome," now available on bioRxiv! 📝 #Abstract : Our study delves into the intriguing role of the microbiome in cancer development and progression. Leveraging spatial transcriptomics, we examined the spatial distribution of microbial RNA in various cancer types, including oral squamous cell carcinoma, head and neck cancer, and colorectal cancer. Our novel method enhances the accuracy of species-level microbiome analysis, offering new insights into microbial distribution and their functional roles within cancer tissues. 🔗 Read the full article here: doi: https://lnkd.in/gehRVNKB This work redefines our understanding of the cancer microbiome and paves the way for future microbiome-based therapies. A big thank you to our incredible team for their dedication and innovation!

🔔 Portrai in LA and Washington D.C. for SelectUSA 2024 Our representative Daeseung Lee, MD, MBA and Jiyeop Lim will be meeting you at the event. We have selected to pitch and our BD Associate Manager, Jiyeop Lim, will be pitching at HealthTech pitching session2 on June 23 at 4PM EDT. The main focus will be on: ✅ Portrai's Petabyte scale database ✅ Why IT companies and Bio-IT VCs must pay attention to Portrai ✅ Fundraising plans for Q4 2024 If you have any questions or interest in our team and business, don't hesitate to contact us before or after the event. Looking forward to connecting with great minds and bright individuals at #SELECTUSA2024 🙌

Here we go #BIOInternational 🙆♀️ Since July 2021, Portrai has been changing the biopharmaceutical industry by using #SpatialTranscriptomics data matched with real world driven clinical data to find the right target to develop the right drug. ✅ Currently, we have information on more than 22 million cells from 29 organs and 52 cancer subtypes. ✅ Our main focus is on finding the partners in antibodies and chemistry to validate our targets and apply them to novel #drugdevelopment suitable for #ADC and #RLT. Beyond drug discovery, we welcome more collaboration throughout the drug development journey. 1️⃣ Together, we can identify novel targets and validate them using petabyte scale clinical samples. 2️⃣ You can also access the efficacy of your molecule using real world patient data. 3️⃣ We can predict off-target toxicity. 🔔If your meeting is full or didn’t have an opportunity to connect with us, Daeseung Lee, MD, MBA and Jiyeop Lim will be at the booth throughout the convention. So stop by and chat with us! More updates are on the way🔥

🎉 #PortraiTME-syngeneic 2+1 이벤트 #한국비임상시험연구회 45차 워크숍을 기념하여 종양미세환경 분석을 하시는 연구자분들께 도움을 드리고자 2+1 이벤트를 진행합니다. ☑ 누구를 대상으로 하나요? MC38, CT26, 4T1, LLC1, PanO2 H&E stained slide에 대한 cell distribution 분석을 원하시는 모든 분들 ☑ 언제까지 하나요? 5월 31일까지 신청서를 제출하신 분들에 한해 이벤트 혜택을 제공합니다. 신청서는 30초 이내에 제출하실 수 있도록 최대한 간단하게 구성했어요. ☑ 신청 프로세스는요? 설문이 제출되면 담당자가 영업일 기준 3일 이내에 연락을 드려 자세한 사항(슬라이드 보낼 주소 등)을 안내해드릴 거에요. 제출 전에 문의사항이 있으신 경우, [email protected] 로 연락해주시면 빠르게 답변드리겠습니다. 오늘 부스에 들려서 궁금한 점도 충분히 물어보시고, 달달구리도 함께 받아가셔요 💜 - 🎉 #PortraiTME-syngeneic 2+1 Event In celebration of the 45th Workshop of the Korean Society of Non-clinical Study, we are offering a special 2+1 event to assist researchers involved in #TumorMicroenvironment analysis. ☑ Who is eligible? Anyone interested in cell distribution analysis of H&E stained slides from MC38, CT26, 4T1, LLC1, and PanO2 models. ☑ When is the deadline? Submit your application by May 31 to take advantage of this event. We've made the application process as simple as possible, taking no more than 30 seconds to complete. ☑ What is the application process? Once your survey is submitted, a dedicated manager will contact you within 3 business days to provide further details (such as the address to send your slides). If you have any questions before submitting, please contact us at [email protected] for a quick response. Visit our booth today to ask any questions you may have and pick up some sweet treats as well💜